Baker Bros. Advisors’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Baker Bros. Advisors’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-683,588	Closed	-$28M	–	99
2024 Q2	$28M	Sell	683,588 -916,412	-57%	-$38.2M	0.36%	36
2024 Q1	$67.6M	Hold	1,600,000	–	–	0.85%	20
2023 Q4	$67.8M	Buy	+1,600,000	New	+$46M	0.77%	16

Other funds holding CERE

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Baker Bros. Advisors's CERE Position: Q3 2024 in Review

Baker Bros. Advisors sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 683,588 shares — an estimated $28M sold.

Baker Bros. Advisors first reported a position in CERE in Q4 2023 and held it in 3 quarters. The position peaked at $67.8M in Q4 2023. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

Baker Bros. Advisors reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
Baker Bros. Advisors sold 683,588 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $28M.
Baker Bros. Advisors first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2023 and held it in 3 quarters.
Baker Bros. Advisors's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $67.8M in Q4 2023.
2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Baker Bros. Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.